The forecasted sales of cardiac glycosides in Finland from 2024 to 2028 remain steady at $0.2 per capita each year. There is no year-on-year variation in percentage, indicating a stable market.
Future Trends: Given the stability in the forecasted sales, it is important to observe potential market disruptors such as the introduction of new competitive treatments, changes in healthcare policy, and shifts in clinical guidelines. Additionally, advancements in technology and healthcare infrastructure could either enhance or inhibit market dynamics in the longer term.
